CoChat
Sign Up
Cited by 53Immune Cell Function and InteractionReproductive System and PregnancyIL-33, ST2, and ILC Pathways

Human leukocyte immunoglobulin-like receptors in health and disease

Open access
Redondo-García, Silvia, Barritt, Christopher, Papagregoriou, Charys, Yeboah, Muchaala, Frendeus, Björn, Cragg, Mark S., Roghanian, Ali·2023·Frontiers in Immunology
DOI 10.3389/fimmu.2023.1282874PMC PMC10679719
Open this paper in CoChat — free accountOpen PDF

Abstract

Human leukocyte immunoglobulin (Ig)-like receptors (LILR) are a family of 11 innate immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are either activating (LILRA) or inhibitory (LILRB) depending on their associated signalling domains (D). With the exception of the soluble LILRA3, LILRAs mediate immune activation, while LILRB1-5 primarily inhibit immune responses and mediate tolerance. Abnormal expression and function of LILRs is associated with a range of pathologies, including immune insufficiency (infection and malignancy) and overt immune responses (autoimmunity and alloresponses), suggesting LILRs may be excellent candidates for targeted immunotherapies. This review will discuss the biology and clinical relevance of this extensive family of immune receptors and will summarise the recent developments in targeting LILRs in disease settings, such as cancer, with an update on the clinical trials investigating the therapeutic targeting of these receptors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1282874

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 311

  1. [1]Levi-Schaffer F Mandelboim O. Inhibitory and coactivating receptors recognising the same ligand: immune homeostasis exploited by pathogens and tumours. Trends Immunol (2018) 39(2): 112–22. doi: 10.1016/j.it.2017.10.001 PMC7106362 29066058 · DOI
  2. [2]Rumpret M Drylewicz J Ackermans LJE Borghans JAM Medzhitov R Meyaard L. Functional categories of immune inhibitory receptors. Nat Rev Immunol (2020) 20(12): 771–80. doi: 10.1038/s41577-020-0352-z 32612208 · DOI
  3. [3]Robert C Schachter J Long GV Arance A Grob JJ Mortier L. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med (2015) 372(26): 2521–32. doi: 10.1056/NEJMoa1503093 25891173 · DOI · Paper page
  4. [4]Edner NM Carlesso G Rush JS Walker LSK. Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov (2020) 19(12): 860–83. doi: 10.1038/s41573-020-0081-9 32939077 · DOI
  5. [5]Brown D Trowsdale J Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens (2004) 64(3): 215–25. doi: 10.1111/j.0001-2815.2004.00290.x 15304001 · DOI
  6. [6]De Louche CD Roghanian A. Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy. JCI Insight (2022) 7(2): e151553. doi: 10.1172/jci.insight.151553 35076022 PMC8855791 · DOI
  7. [7]Hirayasu K Arase H. Leukocyte immunoglobulin-like receptor (LILR). In: Choi S, editor. Encyclopedia of signaling molecules. Cham: Springer International Publishing (2018). p. 2854–61. doi: 10.1007/978-3-319-67199-4_101689 · DOI
  8. [8]Colonna M Samaridis J Cella M Angman L Allen RL O’Callaghan CA. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol (1998) 160(7): 3096–100. doi: 10.4049/jimmunol.160.7.3096 9531263 · DOI
  9. [9]Cosman D Fanger N Borges L Kubin M Chin W Peterson L. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity (1997) 7(2): 273–82. doi: 10.1016/S1074-7613(00)80529-4 9285411 · DOI
  10. [10]Gray KA Yates B Seal RL Wright MW Bruford EA. Genenames.org: the HGNC resources in 2015. Nucleic Acids Res (2015) 43(Database issue): D1079–85. doi: 10.1093/nar/gku1071 PMC4383909 25361968 · DOI
  11. [11]Borges L Hsu ML Fanger N Kubin M Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol (1997) 159(11): 5192–6. doi: 10.4049/jimmunol.159.11.5192 9548455 · DOI
  12. [12]Storm L Bruijnesteijn J de Groot NG Bontrop RE. The genomic organization of the LILR region remained largely conserved throughout primate evolution: implications for health and disease. Front Immunol (2021) 12: 716289. doi: 10.3389/fimmu.2021.716289 34737739 PMC8562567 · DOI
  13. [13]Wilson MJ Torkar M Haude A Milne S Jones T Sheer D. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci USA (2000) 97(9): 4778–83. doi: 10.1073/pnas.080588597 PMC18309 10781084 · DOI
  14. [14]Yang T Qian Y Liang X Wu J Zou M Deng M. LILRB4, an immune checkpoint on myeloid cells. Blood Sci (2022) 4(2): 49– 56. doi: 10.1097/BS9.0000000000000109 35957669 PMC9362873 · DOI
  15. [15]Torkar M Haude A Milne S Beck S Trowsdale J Wilson MJ. Arrangement of the ILT gene cluster: a common null allele of the ILT6 gene results from a 6.7-kbp deletion. Eur J Immunol (2000) 30(12): 3655–62. doi: 10.1002/1521-4141(200012)30:12&lt;3655::AID-IMMU3655<3.0.CO;2-Y 11169408 · DOI
  16. [16]Norman P Carey BS Stephens HF Vaughan R. DNA sequence variation and molecular genotyping of natural killer leukocyte immunoglobulin-like receptor, LILRA3. Immunogenetics (2003) 55(3): 165–71. doi: 10.1007/s00251-003-0561-1 12750859 · DOI
  17. [17]Kuroki K Tsuchiya N Shiroishi M Rasubala L Yamashita Y Matsuta K. Extensive polymorphisms of LILRB1 (ILT2, LIR1) and their association with HLA-DRB1 shared epitope negative rheumatoid arthritis. Hum Mol Genet (2005) 14(16): 2469–80. doi: 10.1093/hmg/ddi247 16014635 · DOI
  18. [18]López-Álvarez MR Jones DC Jiang W Traherne JA Trowsdale J. Copy number and nucleotide variation of the LILR family of myelomonocytic cell activating and inhibitory receptors. Immunogenetics (2014) 66(2): 73– 83. doi: 10.1007/s00251-013-0742-5 24257760 PMC3894450 · DOI
  19. [19]Lewis Marffy AL McCarthy AJ. Leukocyte immunoglobulin-like receptors (LILRs) on human neutrophils: modulators of infection and immunity. Front Immunol (2020) 11: 857. doi: 10.3389/fimmu.2020.00857 32477348 PMC7237751 · DOI · Paper page
  20. [20]Reid BM Permuth JB Chen YA Fridley BL Iversen ES Chen Z. Genome-wide analysis of common copy number variation and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev (2019) 28(7): 1117–26. doi: 10.1158/1055-9965.EPI-18-0833 PMC6606353 30948450 · DOI
  21. [21]Hirayasu K Ohashi J Tanaka H Kashiwase K Ogawa A Takanashi M. Evidence for natural selection on leukocyte immunoglobulin-like receptors for HLA class I in Northeast Asians. Am J Hum Genet (2008) 82(5): 1075–83. doi: 10.1016/j.ajhg.2008.03.012 PMC2427302 18439545 · DOI
  22. [22]Anderson KJ Allen RL. Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells. Immunology (2009) 127(1): 8– 17. doi: 10.1111/j.1365-2567.2009.03097.x 19368561 PMC2678177 · DOI
  23. [23]Zhang M Yang J Zhang J Huang C Liu H Zhang P. Research progress of B subfamily of leucocyte immunoglobulin-like receptors in inflammation. Int J Immunogenet (2023) 50(3): 107–16. doi: 10.1111/iji.12618 37038910 · DOI
  24. [24]Hirayasu K Arase H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J Hum Genet (2015) 60(11): 703–8. doi: 10.1038/jhg.2015.64 26040207 · DOI · Paper page
  25. [25]An H Chandra V Piraino B Borges L Geczy C McNeil HP. Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-α, and interferon-γ. J Rheumatol (2010) 37(8): 1596–606. doi: 10.3899/jrheum.091119 20595277 · DOI
  26. [26]Jones DC Roghanian A Brown DP Chang C Allen RL Trowsdale J. Alternative mRNA splicing creates transcripts encoding soluble proteins from most LILR genes. Eur J Immunol (2009) 39(11): 3195–206. doi: 10.1002/eji.200839080 19658091 · DOI
  27. [27]Beinhauer BG McBride JM Graf P Pursch E Bongers M Rogy M. Interleukin 10 regulates cell surface and soluble LIR-2 (CD85d) expression on dendritic cells resulting in T cell hyporesponsiveness in vitro. Eur J Immunol (2004) 34(1): 74– 80. doi: 10.1002/eji.200324550 14971032 · DOI
  28. [28]Borges L Kubin M Kuhlman T. LIR9, an immunoglobulin-superfamily–activating receptor, is expressed as a transmembrane and as a secreted molecule. Blood (2002) 101(4): 1484–6. doi: 10.1182/blood-2002-05-1432 12393390 · DOI
  29. [29]Jones DC Kosmoliaptsis V Apps R Lapaque N Smith I Kono A. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol (2011) 186(5): 2990–7. doi: 10.4049/jimmunol.1003078 21270408 · DOI
  30. [30]Colonna M Nakajima H Navarro F López-Botet M. A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukocyte Biol (1999) 66(3): 375–81. doi: 10.1002/jlb.66.3.375 10496306 · DOI
  31. [31]Chapman TL Heikema AP West AP Jr. Bjorkman PJ. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Immunity (2000) 13(5): 727–36. doi: 10.1016/s1074-7613(00)00071-6 11114384 · DOI
  32. [32]Nam G Shi Y Ryu M Wang Q Song H Liu J. Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding. Protein Cell (2013) 4(10): 761–70. doi: 10.1007/s13238-013-3908-x PMC4875434 23955630 · DOI
  33. [33]Willcox BE Thomas LM Chapman TL Heikema AP West AP Jr. Bjorkman PJ. Crystal structure of LIR-2 (ILT4) at 1.8 A: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18. BMC Struct Biol (2002) 2: 6. doi: 10.1186/1472-6807-2-6 12390682 PMC130215 · DOI
  34. [34]Wang Q Song H Cheng H Qi J Nam G Tan S. Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cell Mol Immunol (2020) 17(9): 966–75. doi: 10.1038/s41423-019-0258-5 PMC7609294 31273318 · DOI
  35. [35]Willcox BE Thomas LM Bjorkman PJ. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol (2003) 4(9): 913–9. doi: 10.1038/ni961 12897781 · DOI
  36. [36]Cheng H Mohammed F Nam G Chen Y Qi J Garner LI. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance. J Biol Chem (2011) 286(20): 18013–25. doi: 10.1074/jbc.M111.221028 PMC3093875 21454581 · DOI
  37. [37]Chen Y Gao F Chu F Peng H Zong L Liu Y. Crystal structure of myeloid cell activating receptor leukocyte Ig-like receptor A2 (LILRA2/ILT1/LIR-7) domain swapped dimer: molecular basis for its non-binding to MHC complexes. J Mol Biol (2009) 386(3): 841–53. doi: 10.1016/j.jmb.2009.01.006 19230061 · DOI
  38. [38]Shiroishi M Kajikawa M Kuroki K Ose T Kohda D Maenaka K. Crystal structure of the human monocyte-activating receptor, “Group 2” leukocyte Ig-like receptor A5 (LILRA5/LIR9/ILT11). J Biol Chem (2006) 281(28): 19536–44. doi: 10.1074/jbc.M603076200 16675463 · DOI
  39. [39]Takai T. Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology (2005) 115(4): 433–40. doi: 10.1111/j.1365-2567.2005.02177.x PMC1782189 16011512 · DOI
  40. [40]Vlieg HC Huizinga EG Janssen BJC. Structure and flexibility of the extracellular region of the PirB receptor. J Biol Chem (2019) 294(12): 4634–43. doi: 10.1074/jbc.RA118.004396 PMC6433079 30674550 · DOI
  41. [41]Deng M Chen H Liu X Huang R He Y Yoo B. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Antib Ther (2021) 4(1): 16– 33. doi: 10.1093/abt/tbab002 33928233 PMC7944505 · DOI · Paper page
  42. [42]Uehara T Bléry M Kang D-W Chen C-C Ho LH Gartland GL. Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B. J Clin Invest (2001) 108(7): 1041–50. doi: 10.1172/JCI12195 PMC200947 11581305 · DOI
  43. [43]Kubagawa H Chen C-C Le Hong H Shimada T Gartland L Mashburn C. Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B. J Exp Med (1999) 189(2): 309–18. doi: 10.1084/jem.189.2.309 PMC2192985 9892613 · DOI
  44. [44]Kubagawa H Burrows PD Cooper MD. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci USA (1997) 94(10): 5261–6. doi: 10.1073/pnas.94.10.5261 PMC24666 9144225 · DOI · Paper page
  45. [45]Pereira S Zhang H Takai T Lowell CA. The inhibitory receptor PIR-B negatively regulates neutrophil and macrophage integrin signaling. J Immunol (2004) 173(9): 5757–65. doi: 10.4049/jimmunol.173.9.5757 15494528 · DOI
  46. [46]Munitz A McBride ML Bernstein JS Rothenberg ME. A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. Blood (2008) 111(12): 5694–703. doi: 10.1182/blood-2007-12-126748 PMC2964258 18316626 · DOI
  47. [47]Baruch-Morgenstern NB Shik D Moshkovits I Itan M Karo-Atar D Bouffi C. Paired immunoglobulin-like receptor A is an intrinsic, self-limiting suppressor of IL-5-induced eosinophil development. Nat Immunol (2014) 15(1): 36– 44. doi: 10.1038/ni.2757 24212998 PMC3869881 · DOI
  48. [48]Shiroishi M Kuroki K Rasubala L Tsumoto K Kumagai I Kurimoto E. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA (2006) 103(44): 16412–7. doi: 10.1073/pnas.0605228103 PMC1637596 17056715 · DOI
  49. [49]Abdallah F Coindre S Gardet M Meurisse F Naji A Suganuma N. Leukocyte immunoglobulin-like receptors in regulating the immune response in infectious diseases: A window of opportunity to pathogen persistence and a sound target in therapeutics. Front Immunol (2021) 12: 717998. doi: 10.3389/fimmu.2021.717998 34594332 PMC8478328 · DOI
  50. [50]Lichterfeld M Yu XG. The emerging role of leukocyte immunoglobulin-like receptors (LILRs) in HIV-1 infection. J Leukocyte Biol (2012) 91(1): 27– 33. doi: 10.1189/jlb.0811442 22028331 PMC3250304 · DOI
  51. [51]Huang J Burke PS Cung TDH Pereyra F Toth I Walker BD. Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol (2010) 84(18): 9463–71. doi: 10.1128/JVI.01009-10 PMC2937602 20631139 · DOI
  52. [52]Lamarthée B Genet C Cattin F Danger R Giral M Brouard S. Single-cell mapping of leukocyte immunoglobulin-like receptors in kidney transplant rejection. Front Transplant (2022) 1: 952785. doi: 10.3389/frtra.2022.952785 PMC11235271 38994376 · DOI
  53. [53]Sloane DE Tedla N Awoniyi M MacGlashan DW Borges L Austen KF. Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition. Blood (2004) 104(9): 2832–9. doi: 10.1182/blood-2004-01-0268 15242876 · DOI
  54. [54]Tedla N Bandeira-Melo C Tassinari P Sloane DE Samplaski M Cosman D. Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci (2003) 100(3): 1174–9. doi: 10.1073/pnas.0337567100 PMC298746 12529506 · DOI
  55. [55]Hirayasu K Saito F Suenaga T Shida K Arase N Oikawa K. Microbially cleaved immunoglobulins are sensed by the innate immune receptor LILRA2. Nat Microbiol (2016) 1: 16054. doi: 10.1038/nmicrobiol.2016.54 27572839 · DOI
  56. [56]Lu HK Mitchell A Endoh Y Hampartzoumian T Huynh O Borges L. LILRA2 selectively modulates LPS-mediated cytokine production and inhibits phagocytosis by monocytes. PloS One (2012) 7(3): e33478. doi: 10.1371/journal.pone.0033478 22479404 PMC3316576 · DOI
  57. [57]Ottonello L Ghio M Contini P Bertolotto M Bianchi G Montecucco F. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-β1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion (2007) 47(8): 1395–404. doi: 10.1111/j.1537-2995.2007.01268.x 17655583 · DOI
  58. [58]Nakajima H Samaridis J Angman L Colonna M. Cutting edge: human myeloid cells express an activating ILT receptor (ILT1) that associates with fc receptor γ-chain. J Immunol (1999) 162(1): 5– 8. doi: 10.4049/jimmunol.162.1.5 9886363 · DOI
  59. [59]Lee DJ Sieling PA Ochoa MT Krutzik SR Guo B Hernandez M. LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol (2007) 179(12): 8128–36. doi: 10.4049/jimmunol.179.12.8128 PMC2650749 18056355 · DOI
  60. [60]Goto-Yamaguchi L Yamamoto-Ibusuki M Yamamoto Y Fujiki Y Tomiguchi M Sueta A. Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling. Breast Cancer Res Treat (2018) 172(2): 353–62. doi: 10.1007/s10549-018-4933-5 30151737 · DOI
  61. [61]Bleharski JR Li H Meinken C Graeber TG Ochoa M-T Yamamura M. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science (2003) 301(5639): 1527–30. doi: 10.1126/science.1087785 12970564 · DOI
  62. [62]Mamegano K Kuroki K Miyashita R Kusaoi M Kobayashi S Matsuta K. Association of LILRA2 (ILT1, LIR7) splice site polymorphism with systemic lupus erythematosus and microscopic polyangiitis. Genes Immun (2008) 9(3): 214–23. doi: 10.1038/gene.2008.5 18273033 · DOI
  63. [63]Tedla N An H Borges L Vollmer-Conna U Bryant K Geczy C. Expression of activating and inhibitory leukocyte immunoglobulin-like receptors in rheumatoid synovium: correlations to disease activity. Tissue Antigens (2011) 77(4): 305–16. doi: 10.1111/j.1399-0039.2011.01633.x 21388353 · DOI
  64. [64]Ryu M Chen Y Qi J Liu J Fan Z Nam G. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence. PloS One (2011) 6(4): e19245. doi: 10.1371/journal.pone.0019245 21559424 PMC3084784 · DOI
  65. [65]An H Brettle M Lee T Heng B Lim CK Guillemin GJ. Soluble LILRA3 promotes neurite outgrowth and synapses formation through a high-affinity interaction with Nogo 66. J Cell Sci (2016) 129(6): 1198–209. doi: 10.1242/jcs.182006 26826187 · DOI
  66. [66]Low HZ Reuter S Topperwien M Dankenbrink N Peest D Kabalak G. Association of the LILRA3 deletion with B-NHL and functional characterization of the immunostimulatory molecule. PloS One (2013) 8(12): e81360. doi: 10.1371/journal.pone.0081360 24363809 PMC3867304 · DOI
  67. [67]Xu J Mo Z Ye D Wang M Liu F Jin G. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet (2012) 44(11): 1231–5. doi: 10.1038/ng.2424 PMC4116636 23023329 · DOI
  68. [68]Koch S Goedde R Nigmatova V Epplen JT Muller N de Seze J. Association of multiple sclerosis with ILT6 deficiency. Genes Immun (2005) 6(5): 445–7. doi: 10.1038/sj.gene.6364187 15815690 · DOI
  69. [69]Du Y Su Y He J Yang Y Shi Y Cui Y. Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjögren’s syndrome. Ann Rheumatic Dis (2014) 74: 2070–5. doi: 10.1136/annrheumdis-2013-204441 24906639 · DOI
  70. [70]Kabalak G Dobberstein SB Matthias T Reuter S The YH Dörner T. Association of immunoglobulin-like transcript 6 deficiency with Sjögren’s syndrome. Arthritis Rheumatism (2009) 60(10): 2923–5. doi: 10.1002/art.24804 19790059 · DOI
  71. [71]Du Y Sun F Zhou M Wu X Sun W Jiang Y. The expression and clinical significance of different forms of LILRA3 in systemic lupus erythematosus. Clin Rheumatol (2019) 38(11): 3099–107. doi: 10.1007/s10067-019-04624-z 31209706 · DOI
  72. [72]Du Y Cui Y Liu X Hu F Yang Y Wu X. Contribution of functional LILRA3, but not nonfunctional LILRA3, to sex bias in susceptibility and severity of anti–citrullinated protein antibody–positive rheumatoid arthritis. Arthritis Rheumatol (2014) 66(4): 822–30. doi: 10.1002/art.38308 24757135 · DOI
  73. [73]Liu M Tang Y Du Y Zhang J Hu F Zou Y. Leukocyte Ig-like receptor A3 facilitates inflammation, migration and invasion of synovial tissue-derived fibroblasts via ERK/JNK activation. Rheumatology (2023). doi: 10.1093/rheumatology/kead359 37462532 · DOI
  74. [74]Kabalak G Koch S Dobberstein B The YH Matthias T Schnarr S. Immunoglobulin-like transcripts as risk genes for autoimmunity. Ann N Y Acad Sci (2007) 1110: 10–4. doi: 10.1196/annals.1423.002 17911415 · DOI
  75. [75]Ordóñez D Sanchez AJ Martinez-Rodriguez JE Cisneros E Ramil E Romo N. Multiple sclerosis associates with LILRA3 deletion in Spanish patients. Genes Immun (2009) 10(6): 579–85. doi: 10.1038/gene.2009.34 19421224 · DOI
  76. [76]Wiśniewski A Wagner M Nowak I Bilińska M Pokryszko-Dragan A Jasek M. 6.7-kbp deletion in LILRA3 (ILT6) gene is associated with later onset of the multiple sclerosis in a Polish population. Hum Immunol (2013) 74(3): 353–7. doi: 10.1016/j.humimm.2012.12.006 23238213 · DOI
  77. [77]Wang M Liu M Jia J Shi H Teng J Liu H. Association of the leukocyte immunoglobulin-like receptor A3 gene with neutrophil activation and disease susceptibility in adult-onset still’s disease. Arthritis Rheumatol (2021) 73(6): 1033–43. doi: 10.1002/art.41635 PMC8252061 33381895 · DOI
  78. [78]Cho M Ishida K Chen J Ohkawa J Chen W Namiki S. SAGE library screening reveals ILT7 as a specific plasmacytoid dendritic cell marker that regulates type I IFN production. Int Immunol (2008) 20(1): 155–64. doi: 10.1093/intimm/dxm127 18048391 · DOI
  79. [79]Cao W Bover L. Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev (2010) 234(1): 163–76. doi: 10.1111/j.0105-2896.2009.00867.x PMC2919054 20193018 · DOI
  80. [80]Tsukamoto N Okada S Onami Y Sasaki Y Umezawa K Kawakami Y. Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin Cancer Res (2009) 15(18): 5733–43. doi: 10.1158/1078-0432.CCR-09-0171 19723650 · DOI
  81. [81]Cao W Rosen DB Ito T Bover L Bao M Watanabe G. Plasmacytoid dendritic cell–specific receptor ILT7–FcϵRIγ inhibits Toll-like receptor–induced interferon production. J Exp Med (2006) 203(6): 1399–405. doi: 10.1084/jem.20052454 PMC2118323 16735691 · DOI
  82. [82]Gao Q Mo S Han C Liao X Yang C Wang X. Comprehensive analysis of LILR family genes expression and tumour-infiltrating immune cells in early-stage pancreatic ductal adenocarcinoma. IET Syst Biol (2023) 17(2): 39– 57. doi: 10.1049/syb2.12058 36748687 PMC10116025 · DOI
  83. [83]Goel RR Kotenko SV Kaplan MJ. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat Rev Rheumatol (2021) 17(6): 349–62. doi: 10.1038/s41584-021-00606-1 PMC8077192 33907323 · DOI
  84. [84]Little AJ Vesely MD. Cutaneous lupus erythematosus: current and future pathogenesis-directed therapies. Yale J Biol Med (2020) 93(1): 81– 95. 32226339 PMC7087060
  85. [85]Niebel D de Vos L Fetter T Bragelmann C Wenzel J. Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions. Am J Clin Dermatol (2023) 24(4): 521–40. doi: 10.1007/s40257-023-00774-8 PMC10157137 37140884 · DOI
  86. [86]Ren X Wen W Fan X Hou W Su B Cai P. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell (2021) 184(23): 5838. doi: 10.1016/j.cell.2021.01.053 34767776 PMC8582084 · DOI · Paper page
  87. [87]Mitchell A Rentero C Endoh Y Hsu K Gaus K Geczy C. LILRA5 is expressed by synovial tissue macrophages in rheumatoid arthritis, selectively induces pro-inflammatory cytokines and IL-10 and is regulated by TNF-α, IL-10 and IFN-γ. Eur J Immunol (2008) 38(12): 3459–73. doi: 10.1002/eji.200838415 19009525 · DOI
  88. [88]Bashirova AA Apps R Vince N Mochalova Y Yu XG Carrington M. Diversity of the human LILRB3/A6 locus encoding a myeloid inhibitory and activating receptor pair. Immunogenetics (2014) 66(1): 1– 8. doi: 10.1007/s00251-013-0730-9 24096970 PMC3877738 · DOI
  89. [89]Jones DC Hewitt CR Lopez-Alvarez MR Jahnke M Russell AI Radjabova V. Allele-specific recognition by LILRB3 and LILRA6 of a cytokeratin 8-associated ligand on necrotic glandular epithelial cells. Oncotarget (2016) 7(13): 15618–31. doi: 10.18632/oncotarget.6905 PMC4941265 26769854 · DOI
  90. [90]Mori Y Tsuji S Inui M Sakamoto Y Endo S Ito Y. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol (2008) 181(7): 4742–51. doi: 10.4049/jimmunol.181.7.4742 18802077 · DOI
  91. [91]McIntire RH Sifers T Platt JS Ganacias KG Langat DK Hunt JS. Novel HLA-G-binding leukocyte immunoglobulin-like receptor (LILR) expression patterns in human placentas and umbilical cords. Placenta (2008) 29(7): 631–8. doi: 10.1016/j.placenta.2008.04.007 PMC2505055 18538388 · DOI
  92. [92]Wang J Zhao SJ Wang LL Lin XX Mor G Liao AH. Leukocyte immunoglobulin-like receptor subfamily B: A novel immune checkpoint molecule at the maternal-fetal interface. J Reprod Immunol (2023) 155: 103764. doi: 10.1016/j.jri.2022.103764 36434938 · DOI
  93. [93]Zhang CC. A perspective on LILRBs and LAIR1 as immune checkpoint targets for cancer treatment. Biochem Biophys Res Commun (2022) 633: 64–7. doi: 10.1016/j.bbrc.2022.09.019 36344166 · DOI
  94. [94]Lepin EJM Bastin JM Allan DSJ Roncador G Braud VM Mason DY. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol (2000) 30(12): 3552–61. doi: 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L 11169396 · DOI
  95. [95]Arnold V Cummings J-S Moreno-Nieves UY Didier C Gilbert A Barré-Sinoussi F. S100A9 protein is a novel ligand for the CD85j receptor and its interaction is implicated in the control of HIV-1 replication by NK cells. Retrovirology (2013) 10: 122–. doi: 10.1186/1742-4690-10-122 PMC3826667 24156302 · DOI
  96. [96]Saito F Hirayasu K Satoh T Wang CW Lusingu J Arimori T. Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature (2017) 552(7683): 101–5. doi: 10.1038/nature24994 PMC5748893 29186116 · DOI
  97. [97]Chan KR Ong EZ Tan HC Zhang SL-X Zhang Q Tang KF. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci (2014) 111(7): 2722–7. doi: 10.1073/pnas.1317454111 PMC3932915 24550301 · DOI
  98. [98]Nakayama M Underhill DM Petersen TW Li B Kitamura T Takai T. Paired ig-like receptors bind to bacteria and shape TLR-mediated cytokine production. J Immunol (2007) 178(7): 4250–9. doi: 10.4049/jimmunol.178.7.4250 17371981 · DOI
  99. [99]Saverino D Merlo A Bruno S Pistoia V Grossi CE Ciccone E. Dual effect of CD85/leukocyte ig-like receptor-1/ig-like transcript 2 and CD152 (CTLA-4) on cytokine production by antigen-stimulated human T cells. J Immunol (2002) 168(1): 207–15. doi: 10.4049/jimmunol.168.1.207 11751964 · DOI
  100. [100]Merlo A Saverino D Tenca C Grossi CE Bruno S Ciccone E. CD85/LIR-1/ILT2 and CD152 (Cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the cytolytic activity of human CD4(+) T-cell clones specific for mycobacterium tuberculosis. Infection Immun (2001) 69(10): 6022–9. doi: 10.1128/IAI.69.10.6022-6029.2001 PMC98730 11553539 · DOI
  101. [101]Xu Z Ho S Chang C-C Liu Z Li M Vasilescu ER. ILT3.Fc inhibits the production of exosomes containing inflammatory microRNA in supernatants of alloactivated T cells. Hum Immunol (2014) 75(8): 756–9. doi: 10.1016/j.humimm.2014.05.006 24862932 · DOI
  102. [102]Saverino D Fabbi M Ghiotto F Merlo A Bruno S Zarcone D. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J Immunol (2000) 165(7): 3742–55. doi: 10.4049/jimmunol.165.7.3742 11034379 · DOI
  103. [103]Bahri R Hirsch F Josse A Rouas-Freiss N Bidere N Vasquez A. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol (2006) 176(3): 1331–9. doi: 10.4049/jimmunol.176.3.1331 16424159 · DOI
  104. [104]Morandi F Ferretti E Bocca P Prigione I Raffaghello L Pistoia V. A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis. PloS One (2010) 5(7): e11763. doi: 10.1371/journal.pone.0011763 20668702 PMC2909260 · DOI
  105. [105]Purbhoo MA Liu H Oddos S Owen DM Neil MAA Pageon SV. Dynamics of subsynaptic vesicles and surface microclusters at the immunological synapse. Sci Signaling (2010) 3(121): ra36–r. doi: 10.1126/scisignal.2000645 20460647 · DOI
  106. [106]Naji A Menier C Morandi F Agaugué S Maki G Ferretti E. Binding of HLA-G to ITIM-bearing ig-like transcript 2 receptor suppresses B cell responses. J Immunol (2014) 192(4): 1536–46. doi: 10.4049/jimmunol.1300438 24453251 · DOI
  107. [107]Naji A Menier C Maki G Carosella ED Rouas-Freiss N. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia (2012) 26(8): 1889–92. doi: 10.1038/leu.2012.62 22441169 · DOI
  108. [108]Tenca C Merlo A Merck E Bates EEM Saverino D Simone R. CD85j (Leukocyte ig-like receptor-1/ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells. J Immunol (2005) 174(11): 6757–63. doi: 10.4049/jimmunol.174.11.6757 15905516 · DOI
  109. [109]Cella M Döhring C Samaridis J Dessing M Brockhaus M Lanzavecchia A. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med (1997) 185(10): 1743–51. doi: 10.1084/jem.185.10.1743 PMC2196312 9151699 · DOI
  110. [110]Godal R Bachanova V Gleason M McCullar V Yun GH Cooley S. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant (2010) 16(5): 612–21. doi: 10.1016/j.bbmt.2010.01.019 PMC2854246 20139023 · DOI
  111. [111]Favier B LeMaoult J Lesport E Carosella ED. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J (2010) 24(3): 689–99. doi: 10.1096/fj.09-135194 19841038 · DOI
  112. [112]Villa-Alvarez M Sordo-Bahamonde C Lorenzo-Herrero S Gonzalez-Rodriguez AP Payer AR Gonzalez-Garcia E. Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in chronic lymphocytic leukemia. Front Immunol (2018) 9: 2917. doi: 10.3389/fimmu.2018.02917 30619281 PMC6297751 · DOI
  113. [113]Forte P Pazmany L Matter-Reissmann UB Stussi G Schneider MK Seebach JD. HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J Immunol (2001) 167(10): 6002–8. doi: 10.4049/jimmunol.167.10.6002 11698480 · DOI
  114. [114]Apps R Gardner L Sharkey AM Holmes N Moffett A. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol (2007) 37(7): 1924–37. doi: 10.1002/eji.200737089 PMC2699429 17549736 · DOI
  115. [115]Young NT Waller ECP Patel R Roghanian A Austyn JM Trowsdale J. The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells. Blood (2007) 111(6): 3090–6. doi: 10.1182/blood-2007-05-089771 18094328 · DOI
  116. [116]Fanger NA Cosman D Peterson L Braddy SC Maliszewski CR Borges L. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol (1998) 28(11): 3423–34. doi: 10.1002/(SICI)1521-4141(199811)28:11<3423::AID-IMMU3423>3.0.CO;2-2 9842885 · DOI · Paper page
  117. [117]Barkal AA Weiskopf K Kao KS Gordon SR Rosental B Yiu YY. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol (2018) 19(1): 76– 84. doi: 10.1038/s41590-017-0004-z 29180808 PMC5832354 · DOI
  118. [118]Zou R Zhong X Liang K Zhi C Chen D Xu Z. Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma. BMC Cancer (2023) 23(1): 403. doi: 10.1186/s12885-023-10906-2 37142967 PMC10161664 · DOI
  119. [119]Xu ZJ Zhang XL Jin Y Wang SS Gu Y Ma JC. Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia. Mol Ther Oncolytics (2022) 26: 88– 104. doi: 10.1016/j.omto.2022.05.011 35795094 PMC9233190 · DOI
  120. [120]Zhang Y Lu N Xue Y Zhang M Li Y Si Y. Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance. Mol Med Rep (2012) 5(4): 910–6. doi: 10.3892/mmr.2012.744 PMC3493079 22246571 · DOI
  121. [121]Sun Y Liu J Gao P Wang Y Liu C. Expression of ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer. Chest (2008) 134(4): 783–8. doi: 10.1378/chest.07-1100 18625675 · DOI
  122. [122]Fan J Li J Han J Zhang Y Gu A Song F. Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma. Mol Immunol (2021) 136: 82– 97. doi: 10.1016/j.molimm.2021.05.011 34098344 · DOI
  123. [123]Fan J Wang L Chen M Zhang J Li J Song F. Analysis of the expression and prognosis for leukocyte immunoglobulin-like receptor subfamily B in human liver cancer. World J Surg Oncol (2022) 20(1): 92. doi: 10.1186/s12957-022-02562-w 35321724 PMC8943947 · DOI
  124. [124]Lefebvre S Antoine M Uzan S McMaster M Dausset J Carosella ED. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol (2002) 196(3): 266–74. doi: 10.1002/path.1039 11857488 · DOI
  125. [125]Xu X Yin S Wang Y Zhu Q Zheng G Lu Y. LILRB1+ immune cell infiltration identifies immunosuppressive microenvironment and dismal outcomes of patients with ovarian cancer. Int Immunopharmacol (2023) 119: 110162. doi: 10.1016/j.intimp.2023.110162 37075669 · DOI
  126. [126]Vittrant B Bergeron A Molina OE Leclercq M Legare XP Hovington H. Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. Oncoimmunology (2020) 9(1): 1851950. doi: 10.1080/2162402X.2020.1851950 33299664 PMC7714461 · DOI
  127. [127]Wang X Meng X Zheng Y Jiang J Yang B Liu Y. Increased frequency of ILT2-expressing CD56(dim)CD16(+) NK cells correlates with disease severity of pulmonary tuberculosis. Tuberculosis (Edinb) (2014) 94(5): 469–74. doi: 10.1016/j.tube.2014.03.009 24909369 · DOI
  128. [128]Vlad G Piazza F Colovai A Cortesini R Della Pietra F Suciu-Foca N. Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals. Hum Immunol (2003) 64(5): 483–9. doi: 10.1016/S0198-8859(03)00040-5 12691698 · DOI
  129. [129]O’Connor GM Holmes A Mulcahy F Gardiner CM. Natural Killer cells from long-term non-progressor HIV patients are characterized by altered phenotype and function. Clin Immunol (2007) 124(3): 277–83. doi: 10.1016/j.clim.2007.05.016 17611161 · DOI
  130. [130]Scott-Algara D Arnold V Didier C Kattan T Pirozzi G Barré-Sinoussi F. The CD85j(+) NK cell subset potently controls HIV-1 replication in autologous dendritic cells. PloS One (2008) 3(4): e1975. doi: 10.1371/journal.pone.0001975 18398485 PMC2276866 · DOI
  131. [131]Berg L Riise GC Cosman D Bergström T Olofsson S Kärre K. LIR-1 expression on lymphocytes, and cytomegalovirus disease in lung-transplant recipients. Lancet (2003) 361(9363): 1099–101. doi: 10.1016/S0140-6736(03)12855-3 12672315 · DOI
  132. [132]Saverino D Ghiotto F Merlo A Bruno S Battini L Occhino M. Specific recognition of the viral protein UL18 by CD85j/LIR-1/ILT2 on CD8+ T cells mediates the non-MHC-restricted lysis of human cytomegalovirus-infected cells. J Immunol (2004) 172(9): 5629–37. doi: 10.4049/jimmunol.172.9.5629 15100307 · DOI
  133. [133]Harrison TE Morch AM Felce JH Sakoguchi A Reid AJ Arase H. Structural basis for RIFIN-mediated activation of LILRB1 in malaria. Nature (2020) 587(7833): 309–12. doi: 10.1038/s41586-020-2530-3 PMC7116854 32650338 · DOI
  134. [134]Sakoguchi A Saito F Hirayasu K Shida K Matsuoka S Itagaki S. Plasmodium falciparum RIFIN is a novel ligand for inhibitory immune receptor LILRB2. Biochem Biophys Res Commun (2021) 548: 167–73. doi: 10.1016/j.bbrc.2021.02.033 33647792 · DOI
  135. [135]Moraes AG Ayo CM Elpidio LNS Souza VH Yamanaka AHU Nogueira ML. HLA-G, LILRB1 and LILRB2 variants in zika virus transmission from mother to child in a population from south and southeast of Brazil. Curr Issues Mol Biol (2022) 44(7): 2783–93. doi: 10.3390/cimb44070191 PMC9317030 35877415 · DOI
  136. [136]Ince MN Harnisch B Xu Z Lee S-K Lange C Moretta L. Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function. Immunology (2004) 112(4): 531–42. doi: 10.1046/j.1365-2567.2004.01907.x PMC1782522 15270723 · DOI
  137. [137]Anfossi N Doisne J-M Peyrat M-A Ugolini S Bonnaud O Bossy D. Coordinated expression of ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J Immunol (2004) 173(12): 7223–9. doi: 10.4049/jimmunol.173.12.7223 15585844 · DOI
  138. [138]Zhang Y Tong S Li S Wang X Ren H Yin W. Increased ILT2 expression contributes to dysfunction of CD56(dim)CD16(+)NK cells in chronic hepatitis B virus infection. Antiviral Res (2022) 205: 105385. doi: 10.1016/j.antiviral.2022.105385 35917968 · DOI
  139. [139]Wiendl H Feger U Mittelbronn M Jack C Schreiner B Stadelmann C. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain (2005) 128(11): 2689–704. doi: 10.1093/brain/awh609 16123145 · DOI
  140. [140]Doníz-Padilla L Paniagua AE Sandoval-Correa P Monsiváis-Urenda A Leskela S Marazuela M. Analysis of expression and function of the inhibitory receptor ILT2 in lymphocytes from patients with autoimmune thyroid disease. Eur J Endocrinol (2011) 165(1): 129–36. doi: 10.1530/EJE-11-0109 21551166 · DOI
  141. [141]Monsiváis-Urenda A Niño-Moreno P Abud-Mendoza C Baranda L Layseca-Espinosa E López-Botet M. Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J Autoimmun (2007) 29(2–3): 97– 105. doi: 10.1016/j.jaut.2007.05.003 17601702 · DOI
  142. [142]Monsiváis-Urenda A Gómez-Martin D Santana-de-Anda K Cruz-Martínez J Alcocer-Varela J González-Amaro R. Defective expression and function of the ILT2/CD85j regulatory receptor in dendritic cells from patients with systemic lupus erythematosus. Hum Immunol (2013) 74(9): 1088–96. doi: 10.1016/j.humimm.2013.05.006 23756160 · DOI
  143. [143]Figueroa-Vega N Galindo-Rodríguez G Bajaña S Portales-Pérez D Abud-Mendoza C Sánchez-Torres C. Phenotypic analysis of IL-10-treated, monocyte-derived dendritic cells in patients with systemic lupus erythematosus. Scandinavian J Immunol (2006) 64(6): 668–76. doi: 10.1111/j.1365-3083.2006.01849.x 17083624 · DOI
  144. [144]Baudhuin J Migraine J Faivre V Loumagne L Lukaszewicz A-C Payen D. Exocytosis acts as a modulator of the ILT4-mediated inhibition of neutrophil functions. Proc Natl Acad Sci United States America (2013) 110(44): 17957–62. doi: 10.1073/pnas.1221535110 PMC3816409 24133137 · DOI
  145. [145]Fan X Shi P Dai J Lu Y Chen X Liu X. Paired immunoglobulin-like receptor B regulates platelet activation. Blood (2014) 124(15): 2421–30. doi: 10.1182/blood-2014-03-557645 PMC4192752 25075127 · DOI
  146. [146]Zheng J Umikawa M Cui C Li J Chen X Zhang C. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature (2012) 485(7400): 656–60. doi: 10.1038/nature11095 PMC3367397 22660330 · DOI
  147. [147]Deng M Lu Z Zheng J Wan X Chen X Hirayasu K. A motif in LILRB2 critical for Angptl2 binding and activation. Blood (2014) 124(6): 924–35. doi: 10.1182/blood-2014-01-549162 PMC4126332 24899623 · DOI
  148. [148]Hofer J Forster F Isenman DE Wahrmann M Leitner J Holzl MA. Ig-like transcript 4 as a cellular receptor for soluble complement fragment C4d. FASEB J (2016) 30(4): 1492–503. doi: 10.1096/fj.15-275594 26678451 · DOI
  149. [149]Lu N Li Y Zhang Z Xing J Sun Y Yao S. Human Semaphorin-4A drives Th2 responses by binding to receptor ILT-4. Nat Commun (2018) 9(1): 742. doi: 10.1038/s41467-018-03128-9 29467366 PMC5821868 · DOI
  150. [150]Ristich V Liang S Zhang W Wu J Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol (2005) 35(4): 1133–42. doi: 10.1002/eji.200425741 15770701 · DOI
  151. [151]Manavalan JS Rossi PC Vlad G Piazza F Yarilina A Cortesini R. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transplant Immunol (2003) 11(3–4): 245–58. doi: 10.1016/S0966-3274(03)00058-3 12967778 · DOI
  152. [152]Suciu-Foca N Manavalan JS Scotto L Kim-Schulze S Galluzzo S Naiyer AJ. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol (2005) 5(1): 7– 11. doi: 10.1016/j.intimp.2004.09.003 15589454 · DOI
  153. [153]Chang CC Ciubotariu R Manavalan JS Yuan J Colovai AI Piazza F. Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol (2002) 3(3): 237–43. doi: 10.1038/ni760 11875462 · DOI
  154. [154]Vlad G Liu Z Zhang Q-Y Cortesini R Suciu-Foca N. Immunosuppressive activity of recombinant ILT3. Int Immunopharmacol (2006) 6(13–14): 1889–94. doi: 10.1016/j.intimp.2006.07.017 17161342 · DOI
  155. [155]Kim-Schulze S Scotto L Vlad G Piazza F Lin H Liu Z. Recombinant ig-like transcript 3-fc modulates T cell responses via induction of th anergy and differentiation of CD8+ T suppressor cells. J Immunol (2006) 176(5): 2790–8. doi: 10.4049/jimmunol.176.5.2790 16493035 · DOI
  156. [156]Chang C-C Liu Z Vlad G Qin H Qiao X Mancini DM. Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells. J Immunol (2009) 182(9): 5208–16. doi: 10.4049/jimmunol.0804048 19380766 · DOI
  157. [157]Chang C-C Vlad G D’Agati VD Liu Z Zhang Q-y Witkowski P. BCL6 is required for differentiation of ig-like transcript 3-fc–induced CD8+ T suppressor cells. J Immunol (2010) 185(10): 5714–22. doi: 10.4049/jimmunol.1001732 20935202 · DOI
  158. [158]Suciu-Foca N Feirt N Zhang Q-Y Vlad G Liu Z Lin H. Soluble ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol (2007) 178(11): 7432–41. doi: 10.4049/jimmunol.178.11.7432 17513794 · DOI
  159. [159]Liang S Ristich V Arase H Dausset J Carosella ED Horuzsko A. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6—STAT3 signaling pathway. Proc Natl Acad Sci (2008) 105: 8357–62. doi: 10.1073/pnas.0803341105 PMC2448841 18550825 · DOI
  160. [160]Chen HM van der Touw W Wang YS Kang K Mai S Zhang J. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest (2018) 128(12): 5647–62. doi: 10.1172/JCI97570 PMC6264729 30352428 · DOI
  161. [161]Umiker B Hashambhoy-Ramsay Y Smith J Rahman T Mueller A Davidson R. Inhibition of LILRB2 by a novel blocking antibody designed to reprogram immunosuppressive macrophages to drive T-cell activation in tumors. Mol Cancer Ther (2023) 22(4): 471–84. doi: 10.1158/1535-7163.MCT-22-0351 36780212 · DOI
  162. [162]Liu J Wang L Gao W Li L Cui X Yang H. Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10. Diagn Pathol (2014) 9: 85–. doi: 10.1186/1746-1596-9-85 PMC4045966 24762057 · DOI
  163. [163]Liu J Zhang F He J Wang S Wang L Li J. Tumor-derived Immunoglobulin-like transcript 4 facilitates angiogenesis of colorectal cancer. Am J Cancer Res (2023) 13(2): 419–35. PMC9989613 36895964
  164. [164]Cai Z Wang L Han Y Gao W Wei X Gong R. Immunoglobulin−like transcript 4 and human leukocyte antigen−G interaction promotes the progression of human colorectal cancer. Int J Oncol (2019) 54(6): 1943–54. doi: 10.3892/ijo.2019.4761 PMC6521940 30942436 · DOI
  165. [165]García M Palma MB Verine J Miriuka S Inda AM Errecalde AL. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma. BMC Cancer (2020) 20(1): 624. doi: 10.1186/s12885-020-07113-8 32620162 PMC7333411 · DOI
  166. [166]Singh VK Khan A Xu Y Mai S Zhang L Mishra A. Antibody-mediated LILRB2-receptor antagonism induces human myeloid-derived suppressor cells to kill mycobacterium tuberculosis. Front Immunol (2022) 13: 865503. doi: 10.3389/fimmu.2022.865503 35757769 PMC9229593 · DOI
  167. [167]Brown DP Jones DC Anderson KJ Lapaque N Buerki RA Trowsdale J. The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection. BMC Immunol (2009) 10: 56–. doi: 10.1186/1471-2172-10-56 PMC2773765 19860908 · DOI
  168. [168]Baffari E Fiume D Caiazzo G Sinistro A Natoli S Almerighi C. Upregulation of the inhibitory receptor ILT4 in monocytes from septic patients. Hum Immunol (2013) 74(10): 1244–50. doi: 10.1016/j.humimm.2013.07.012 23911358 · DOI
  169. [169]Lichterfeld M Kavanagh DG Williams KL Moza B Mui SK Miura T. A viral CTL escape mutation leading to immunoglobulin-like transcript 4–mediated functional inhibition of myelomonocytic cells. J Exp Med (2007) 204(12): 2813–24. doi: 10.1084/jem.20061865 PMC2118510 18025130 · DOI
  170. [170]Bashirova AA Martin-Gayo E Jones DC Qi Y Apps R Gao X. LILRB2 interaction with HLA class I correlates with control of HIV-1 infection. PloS Genet (2014) 10(3): e1004196. doi: 10.1371/journal.pgen.1004196 24603468 PMC3945438 · DOI
  171. [171]Kawaguchi Y Matsubayashi J Kawakami Y Nishida R Kurihara Y Takei K. LOTUS suppresses amyloid beta-induced dendritic spine elimination through the blockade of amyloid beta binding to PirB. Mol Med (2022) 28(1): 154. doi: 10.1186/s10020-022-00581-7 36510132 PMC9743548 · DOI
  172. [172]Kim T Vidal GS Djurisic M William CM Birnbaum ME Garcia KC. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science (2013) 341(6152): 1399–404. doi: 10.1126/science.1242077 PMC3853120 24052308 · DOI · Paper page
  173. [173]Stallone G Pontrelli P Infante B Gigante M Netti GS Ranieri E. Rapamycin induces ILT3highILT4high dendritic cells promoting a new immunoregulatory pathway. Kidney Int (2014) 85(4): 888–97. doi: 10.1038/ki.2013.337 24107844 · DOI
  174. [174]Borges L Cosman D. LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells. Cytokine Growth Factor Rev (2000) 11(3): 209–17. doi: 10.1016/s1359-6101(00)00007-1 10817964 · DOI
  175. [175]Zhou J Wang Y Huang G Yang M Zhu Y Jin C. LilrB3 is a putative cell surface receptor of APOE4. Cell Res (2023) 33(2): 116–30. doi: 10.1038/s41422-022-00759-y PMC9892561 36588123 · DOI
  176. [176]Zhao Y van Woudenbergh E Zhu J Heck AJR van Kessel KPM de Haas CJC. The orphan immune receptor LILRB3 modulates fc receptor-mediated functions of neutrophils. J Immunol (2020) 204(4): 954–66. doi: 10.4049/jimmunol.1900852 PMC7617070 31915259 · DOI
  177. [177]Yeboah M Papagregoriou C Jones DC Chan HTC Hu G McPartlan JS. LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. JCI Insight (2020) 5(18): e141593. doi: 10.1172/jci.insight.141593 32870822 PMC7526549 · DOI
  178. [178]Perna F Berman SH Soni RK Mansilla-Soto J Eyquem J Hamieh M. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell (2017) 32(4): 506– 19 e5. doi: 10.1016/j.ccell.2017.09.004 29017060 PMC7025434 · DOI
  179. [179]Shi W Zhang F Chen X Wang S Zhang H Yang Z. Tumor-derived immunoglobulin like transcript 5 induces suppressive immunocyte infiltration in colorectal cancer. Cancer Sci (2022) 113(6): 1939–54. doi: 10.1111/cas.15360 PMC9207357 35377522 · DOI
  180. [180]Renauer PA Saruhan-Direskeneli G Coit P Adler A Aksu K Keser G. Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in takayasu arteritis in a genome-wide association study. Arthritis Rheumatol (2015) 67(5): 1361–8. doi: 10.1002/art.39035 PMC4414813 25604533 · DOI
  181. [181]Pfistershammer K Lawitschka A Klauser C Leitner J Weigl R Heemskerk MH. Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients. Blood (2009) 114(11): 2323–32. doi: 10.1182/blood-2008-10-183814 19617579 · DOI
  182. [182]Inui M Hirota S Hirano K Fujii H Sugahara-Tobinai A Ishii T. Human CD43+ B cells are closely related not only to memory B cells phenotypically but also to plasmablasts developmentally in healthy individuals. Int Immunol (2015) 27(7): 345–55. doi: 10.1093/intimm/dxv009 25744616 · DOI
  183. [183]Mitsune A Yamada M Fujino N Numakura T Ichikawa T Suzuki A. Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation. Respir Res (2021) 22(1): 232. doi: 10.1186/s12931-021-01828-3 34425800 PMC8383377 · DOI
  184. [184]Sharma N Atolagbe OT Ge Z Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med (2021) 218(7): e20201811. doi: 10.1084/jem.20201811 33974041 PMC8117208 · DOI
  185. [186]Xu Z Chang CC Li M Zhang QY Vasilescu EM D’Agati V. ILT3.Fc-CD166 interaction induces inactivation of p70 S6 kinase and inhibits tumor cell growth. J Immunol (2018) 200(3): 1207–19. doi: 10.4049/jimmunol.1700553 29263213 · DOI
  186. [187]Su MT Inui M Wong YL Takahashi M Sugahara-Tobinai A Ono K. Blockade of checkpoint ILT3/LILRB4/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB/Yaa mice. Int Immunol (2021) 33(8): 447–58. doi: 10.1093/intimm/dxab028 34089617 · DOI
  187. [188]Wang Y Yufan S Deng S Song T Wang Y Xu J. Galectin-8 is a major ligand of LILRB4 prompting MDSC functions in the tumor microenvironment. Biorxiv (2022). doi: 10.1101/2022.07.27.501694 · DOI
  188. [189]Park M Raftery MJ Thomas PS Geczy CL Bryant K Tedla N. Leukocyte immunoglobulin-like receptor B4 regulates key signalling molecules involved in FcγRI-mediated clathrin-dependent endocytosis and phagocytosis. Sci Rep (2016) 6: 35085. doi: 10.1038/srep35085 27725776 PMC5057125 · DOI
  189. [190]Li Z Deng M Huang F Jin C Sun S Chen H. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol (2020) 17(3): 272–82. doi: 10.1038/s41423-019-0321-2 PMC7052276 31700117 · DOI
  190. [191]Dobrowolska H Gill KZ Serban G Ivan E Li Q Qiao PY. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytometry Part B-Clinical Cytometry (2013) 84B(1): 21–9. doi: 10.1002/cyto.b.21050 23027709 · DOI
  191. [192]Atfy M Ebian H Elhefni A Atteia H. The usefulness of immunoglobulin-like transcript-3 receptor expression in the diagnosis of acute myeloid leukemia with monocytic differentiation. Egyptian J Haematol (2014) 39(3): 122–7. doi: 10.4103/1110-1067.148235 · DOI
  192. [193]Di Meo F Iyer A Akama K Cheng R Yu C Cesarano A. A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Rep Med (2023) 4(7): 101110. doi: 10.1016/j.xcrm.2023.101110 37467717 PMC10394163 · DOI
  193. [194]Liu J Lu CX Zhang F Lv W Liu C. Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer. Pathol Res Pract (2018) 214(10): 1621–5. doi: 10.1016/j.prp.2018.07.026 30126665 · DOI
  194. [195]de Goeje PL Bezemer K Heuvers ME Dingemans A-MC Groen HJ Smit EF. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. OncoImmunology (2015) 4(7): e1014242. doi: 10.1080/2162402X.2015.1014242 26140237 PMC4485803 · DOI
  195. [196]Li J Gao A Zhang F Wang S Wang J Wang J. ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer. Cancer Lett (2021) 501: 263–76. doi: 10.1016/j.canlet.2020.10.048 33152402 · DOI
  196. [197]Tomic S Dokic J Stevanovic D Ilic N Gruden-Movsesijan A Dinic M. Reduced expression of autophagy markers and expansion of myeloid-derived suppressor cells correlate with poor T cell response in severe COVID-19 patients. Front Immunol (2021) 12: 614599. doi: 10.3389/fimmu.2021.614599 33692788 PMC7937809 · DOI
  197. [198]Patel H Ashton NJ Dobson RJB Andersson LM Yilmaz A Blennow K. Proteomic blood profiling in mild, severe and critical COVID-19 patients. Sci Rep (2021) 11(1): 6357. doi: 10.1038/s41598-021-85877-0 33737684 PMC7973581 · DOI
  198. [199]Waschbisch A Sanderson N Krumbholz M Vlad G Theil D Schwab S. Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients. PloS One (2014) 9(12): e115488. doi: 10.1371/journal.pone.0115488 25551576 PMC4281069 · DOI
  199. [200]Jensen MA Yanowitch RN Reder AT White DM Arnason BGW. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon β-1b. Multiple Sclerosis (2010) 16(1): 30–8. doi: 10.1177/1352458509352794 20007427 · DOI
  200. [201]Jensen MA Patterson KC Kumar AA Kumabe M Franek BS Niewold TB. Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients. Ann Rheumatic Dis (2013) 72(4): 596– 601. doi: 10.1136/annrheumdis-2012-202024 PMC3910490 22904259 · DOI

200 of 311 shown

Cited by

Sorted by citations

Authors
Redondo-García, S., Barritt, C., Papagregoriou, C., Yeboah, M., Frendeus, B., Cragg, M. S., & Roghanian, A.
Affiliations
  • Southampton General Hospital (GB)
  • Glasgow Royal Infirmary (GB)
Corresponding author
Roghanian, Ali
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2023-11-13
Volume
14
Pages
1282874-1282874
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2023.1282874
PMC
PMC10679719
OpenAlex
W4388646676
Cited by
53
References
2
Citations by year
2026: 24 · 2025: 16 · 2024: 13
FWCI
1.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Research UK (DRCRPG‐May23/100001, 24721)
  • University of Southampton
  • Blood Cancer UK (14043)
  • Directorate for Biological Sciences
  • Medical Research Council
  • Biotechnology and Biological Sciences Research Council
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
Keywords
leukocyte immunoglobulin-like receptors, innate immune receptors, immunomodulation, immune tolerance, autoimmunity, alloresponse, cancer immunotherapy, clinical trials
MeSH terms
Humans, Immunoglobulins, Leukocytes, Receptors, Immunologic, Myeloid Cells, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review